Insights
Search Results
Client Highlights
6.02.26
Firm Advises Noctrix on Acquisition by Resmed
On June 1, 2026, Resmed, a medical device company that develops, manufactures, and distributes medical equipment for the diagnosis, treatment, and management of respiratory disorders, announced it has closed on its acquisition of Noctrix Health, a medical device company that developed and manufactures a novel therapy to treat drug-refractory Restless Legs Syndrome (RLS) for $340 million. Wilson Sonsini Goodrich & Rosati advised Noctrix on the transaction.
Client Highlights
4.14.26
Firm Advises Getlabs on Acquisition by Function
On April 8, 2026, Function Health announced it has acquired Getlabs, a leading mobile healthcare platform that brings licensed specialists directly to one's location. The acquisition allows for the continuation of Getlab’s nationwide network of providers, health systems, and partners, while advancing Function's broader commitment to making healthcare more accessible by building experiences around member needs. Wilson Sonsini Goodrich & Rosati advised Getlabs on the transaction.
Client Highlights
11.18.25
Firm Advises ABL Bio on Strategic Alliance and Equity Investment with Eli Lilly
On November 14, 2025, ABL Bio announced a broad strategic research and development alliance with Eli Lilly and Company, establishing a multi-program collaboration to advance next-generation therapeutics using ABL Bio’s Grabody Platform. Wilson Sonsini Goodrich & Rosati advised ABL Bio on the license, research, and collaboration agreement, which is valued at up to $2.602 billion, including a $40 million upfront payment. Through this partnership, ABL Bio and Lilly will jointly explore and develop multiple therapeutic modalities across a range of disease areas, marking a significant expansion of ABL Bio’s platform-driven global collaborations.
Client Highlights
6.26.25
Wilson Sonsini Advises Materna Medical on $20 Million Series B2
On June 17, 2025, Materna Medical, Inc., a leading innovator in women’s pelvic health solutions, announced the completion of a recent close within an ongoing $20 million Series B2 financing round. The round welcomed new funds GLIN Impact Capital, Wealthing VC Club, and Citrine Angels, and was led by InnovaHealth Partners and other key existing investors Wavemaker Three-Sixty Health, Kimera Limited, Women’s Venture Capital Fund, and Golden Seeds. Wilson Sonsini Goodrich & Rosati advised Materna Medical on the transaction.
Client Highlights
5.21.25
Wilson Sonsini Advises Halo Labs on Acquisition by Waters
On May 21, 2025, Waters Corporation announced that it acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. Wilson Sonsini Goodrich & Rosati advised Halo Labs on the transaction.
Client Highlights
2.21.25
Wilson Sonsini Advises Anaerobe Systems on Acquisition by Biolog
On February 12, 2025, Biolog, a leading provider of cell-based microbial and phenotypic profiling products and multiomic microbial identification services, announced the acquisition of Anaerobe Systems. The acquisition will be funded through a financing led by J.P. Morgan Life Sciences Private Capital with participation from existing investors BroadOak Capital Partners and Research Corporation Technologies. Wilson Sonsini Goodrich & Rosati advised Anaerobe Systems on the transaction.
Client Highlights
8.19.24
Wilson Sonsini Advises Neptune Medical on $97 Million Series D Financing
On August 15, 2024, Neptune Medical, a leader in medical device innovation, announced the completion of a $97 million Series D financing. Sonder Capital and Olympus Corporation of the Americas were significant participants in the round, which included investments from other existing and new investors. Wilson Sonsini Goodrich & Rosati advised Neptune Medical on the transaction.
The financing will strengthen Neptune Medical as a gastrointestinal-focused company expanding into robotics for GI disease, as evidenced by the recent appointment of medical robotics pioneer Dr. Fred Moll as chairman of the company’s board.
Neptune Medical also announced the successful spinout of its subsidiary, Jupiter Endovascular, which is developing a new class of endovascular procedures to bring the precision and control of direct surgical access to catheter-based interventions. Wilson Sonsini will represent Jupiter Endovascular moving forward.
The Wilson Sonsini team that advised Neptune Medical on the Series D financing included James Huie, Brian Appel, MJ Han, and Ryan Isola.
For more information, please see Neptune Medical’s news release. Additional coverage is available in Fierce Biotech.
The financing will strengthen Neptune Medical as a gastrointestinal-focused company expanding into robotics for GI disease, as evidenced by the recent appointment of medical robotics pioneer Dr. Fred Moll as chairman of the company’s board.
Neptune Medical also announced the successful spinout of its subsidiary, Jupiter Endovascular, which is developing a new class of endovascular procedures to bring the precision and control of direct surgical access to catheter-based interventions. Wilson Sonsini will represent Jupiter Endovascular moving forward.
The Wilson Sonsini team that advised Neptune Medical on the Series D financing included James Huie, Brian Appel, MJ Han, and Ryan Isola.
For more information, please see Neptune Medical’s news release. Additional coverage is available in Fierce Biotech.
Newsletters
1.04.24
The Life Sciences Report – January 2024
This issue features articles on the firm’s Business Advisory Practice supporting Nervosave Therapeutics’ U.S. expansion; the USPTO’s forthcoming guidance on AI innovation protection; option pool sizes for life sciences companies; life sciences venture financings for clients in 2H 2022 and 1H 2023; and Congress’s attempts to improve medical diagnostics patent eligibility. It also includes a client interview with SonoThera CEO Kenneth Greenberg, an article on DOJ’s incentives for life sciences companies to self-disclose misconduct, and a Q&A with Ed Shenkan on decreasing risk from medical device concept to commercialization, as well as details on recent life sciences-focused NextGen VC Forums hosted by Wilson Sonsini and LaunchBio, the 28th annual Phoenix Conference and 2023 Life Sciences Investment Forum, and select life sciences client highlights.
Press Releases
12.04.23
Wilson Sonsini Goodrich & Rosati Elects 20 New Partners
Contact:
Kimberly Brooks
Wilson Sonsini
+1 212.453.2881
kbrooks@wsgr.com
Kimberly Brooks
Wilson Sonsini
+1 212.453.2881
kbrooks@wsgr.com
Newsletters
6.07.23
The Life Sciences Report – June 2023
This latest issue features an article on Enliven Therapeutics’ reverse merger with Imara and concurrent financing, including an interview with Enliven co-founder and CEO Sam Kintz; a piece on trends in digital health following the end of the COVID-19 public health emergency; and an analysis of life sciences venture financings in which clients participated across the first and second halves of 2022. It also includes details on the life sciences-focused NextGen VC Forum hosted by Wilson Sonsini and LaunchBio, a preview of the U.S.-Japan Healthcare Connection’s trade mission and roadshow for healthcare companies, a recap of the firm’s inaugural 1L Life Sciences Summit, and select life sciences client highlights, among other content.
Client Highlights
7.05.22
Wilson Sonsini Advises Respiratory Motion on $44 Million Acquisition by Senzime
On July 1, 2022, Senzime completed the acquisition of 100 percent of the shares in Respiratory Motion, as was made public on June 1, 2022. Senzime's board of directors has resolved to issue 2,127,537 new shares to the sellers of Respiratory Motion at a subscription price of SEK18.59 per share. Respiratory Motion is a Boston-based medtech company that develops and commercializes systems for the monitoring of respiratory function and other vital signs. The company's solution—ExSpiron—is the only non-invasive system on the market that monitors patients' breathing volume and real-time breathing frequency. The system is CE and FDA approved and validated on over 6,000 patients.
Client Highlights
10.09.20
Wilson Sonsini Advises Avail Medsystems in $100 Million Series B
On October 7, 2020, Avail Medsystems, the medical technology company pioneering telemedicine for the procedure room (Procedural Telemedicine™), announced that it has raised $100 million in Series B funding led by D1 Capital Partners, with participation from 8VC and existing investors. Wilson Sonsini Goodrich & Rosati represented Avail Medsystems in the transaction.